Ozempic (semaglutide SC once-weekly) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 12 Diseases   138 Trials   138 Trials   3994 News 


«12...1819202122232425262728...3940»
  • ||||||||||  Journal:  Drugs and devices for weight management. (Pubmed Central) -  Jun 4, 2022   
    Oral semaglutide is effective across a range of baseline subgroups of Japanese patients with type 2 diabetes, with no unexpected safety findings. No abstract available
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. (Pubmed Central) -  May 29, 2022   
    Semaglutide 2.4 mg treatment could dramatically improve clinical approaches to weight management, but the relatively high cost might prevent patients accessing treatment. Further research exploring the cost-effectiveness of subcutaneous semaglutide 2.4 mg is required.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Review, Journal:  Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. (Pubmed Central) -  May 26, 2022   
    The approval of once daily liraglutide, 3.0 mg, and once weekly semaglutide, 2.4 mg, for chronic weight management provides a novel effective strategy against obesity...Moreover, people with diabetes may have had obesity for longer and may be less adherent to exercise, which seems to potentiate the effects of GLP-1 RA. Emerging multimodal approaches combining peptides targeting receptors at different levels might therefore be of additional benefit particularly in patients with diabetes.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    New trial:  OTID: Obesity Treatment to Improve Diabetes (clinicaltrials.gov) -  May 24, 2022   
    P=N/A,  N=72, Not yet recruiting, 
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Trial completion date, Trial primary completion date:  SWIFT: Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV (clinicaltrials.gov) -  May 23, 2022   
    P=N/A,  N=80, Not yet recruiting, 
    Emerging multimodal approaches combining peptides targeting receptors at different levels might therefore be of additional benefit particularly in patients with diabetes. Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: May 2024 --> Nov 2024
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  In brief: Higher-dose semaglutide (Ozempic) for type 2 diabetes. (Pubmed Central) -  May 18, 2022   
    This study helps contextualize the results of semaglutide clinical trials. No abstract available
  • ||||||||||  ZP 8396 / Zealand Pharma
    Antidiabetic Potential of Novel, Long-Acting Amylin Analogue ZP8396 in ZDF Rats (356 (Level 3); Board No. 213) -  May 11, 2022 - Abstract #ADA2022ADA_2464;    
    Clinical efficacy has been demonstrated with short-acting amylin analogue pramlintide...Also, ZP8396 significantly reduced plasma glucagon levels, reaching a 55% difference in ZP8396-treated diabetic rats vs. vehicle group at 24 h post-dose (p <0.05).In conclusion, in diabetic rat ZP8396 improved glycaemic status, supporting that long-acting amylin analogues may provide future valuable therapeutic options to manage diabetes. Further preclinical characterization of the antidiabetes effects of long-term treatment with ZP8396 is ongoing.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
    COVID-19 Outcomes in Patients Who Started GLP1-RAs during Hospitalization (Poster Hall (Halls D-E); Board No. 89) -  May 11, 2022 - Abstract #ADA2022ADA_2106;    
    Almost all patients were treated with once-weekly subcutaneous semaglutide, while dulaglutide was administered in 2 cases...Dementia resulted the only other independent correlate of the outcome. These preliminary results suggest that the addition of GLP1-RAs to standard care during hospitalization for SARS-CoV2 infection could play a role in improving clinical outcomes in patients with COVID-19 and T2D or IHH: at the best of our knowledge this is the first study showing such an effect when GLP1-RAs were started during hospitalization.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity (Poster Hall (Halls D-E); Board No. 2) -  May 11, 2022 - Abstract #ADA2022ADA_1872;    
    Risk score changes mirrored weight loss, which was 17% with sema vs. 3% with PBO in STEP 1, and in STEP 4 was ‍11% for wks 0-20 with sema, and a further 9% with continued sema vs. a 6% regain with switch to PBO for wks 20-68.In summary, treatment with sema reduces the 10-yr risk of T2D by ~60% regardless of initial glycemic status, with sustained treatment required to maintain this benefit. These data suggest sema could help prevent T2D in people with obesity.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Study Design and Baseline Profile for Patients with Type 2 Diabetes in the Semaglutide Once-Weekly Randomized Pragmatic Trial (SEPRA) (Poster Hall (Halls D-E); Board No. 752) -  May 11, 2022 - Abstract #ADA2022ADA_1466;    
    P4
    Of note, 86.9% of patients had HbA1c >7.0% and most required sizeable reductions in HbA1c to reach the clinician-assigned individualized target. SEPRA will provide real-world evidence on the long-term effectiveness of semaglutide in a population with a broad range of HbA1c levels and other clinical characteristics when used as intensification early on in usual T2D care practice settings.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Effect Of Once-Weekly Semaglutide on Weight Change and Metabolic Control in People with Type 1 Diabetes—Six-Months Results from the Real-World STEMT Trial (Poster Hall (Halls D-E); Board No. 751) -  May 11, 2022 - Abstract #ADA2022ADA_1465;    
    SEPRA will provide real-world evidence on the long-term effectiveness of semaglutide in a population with a broad range of HbA1c levels and other clinical characteristics when used as intensification early on in usual T2D care practice settings. Adding semaglutide 1.0 mg once-weekly in people with T1D was safe, well-tolerated and resulted in promising effects on weight, insulin requirement and glycemic control.Acknowledgements: JM and HDW claim shared first authorship.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity (Exhibit Hall (Halls B-C) ePoster Theater B; Board No. 2) -  May 11, 2022 - Abstract #ADA2022ADA_788;    
    Risk score changes mirrored weight loss, which was 17% with sema vs. 3% with PBO in STEP 1, and in STEP 4 was ‍11% for wks 0-20 with sema, and a further 9% with continued sema vs. a 6% regain with switch to PBO for wks 20-68.In summary, treatment with sema reduces the 10-yr risk of T2D by ~60% regardless of initial glycemic status, with sustained treatment required to maintain this benefit. These data suggest sema could help prevent T2D in people with obesity.
  • ||||||||||  Journal, HEOR:  Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective. (Pubmed Central) -  May 10, 2022   
    A budget impact model that captures the cost of control model was constructed to simulate hypothetical patient on six treatment options: a current mix of 60% liraglutide and 40% dulaglutide, semaglutide, liraglutide, dulaglutide, exenatide, and lixisenatide...These results were confirmed in the PSA. Semaglutide 1 mg once weekly was the most economically favorable GLP1RA; associated with the least CCPPPY, and amount of SAR spent to achieve HbA1c of ≤6.50%/<7.00% versus all other GLP1RAs.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Semaglutide for the Treatment of Weight Gain Associated with Antipsychotics in Patients with Schizophrenia: Proposed Design for a Randomized Controlled Trial (Palomino Ballroom 4-10) -  May 6, 2022 - Abstract #ASCP2022ASCP_188;    
    Metformin, topiramate, lorcaserin, orlistat, naltrexone, and samidorphan are among the most studied medications to prevent or reverse the weight gain associated with antipsychotics, which have shown to mildly attenuate the weight gain effect of antipsychotics and result in two-to-five-kilogram weight reduction compared to placebo...Using semaglutide as an adjunctive agent to antipsychotics in patients with schizophrenia can potentially attenuate the weight gain caused by antipsychotics and may cause significant further weight reduction. Accreditation Post-Test Question Post-Test Question Semaglutide is approved by FDA for the treatment of:
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Change in KDIGO Kidney Risk Category With Semaglutide Treatment—A Post Hoc Analysis of the Sustain 6 Trial (Mini-Orals Hall) -  May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_1282;    
    P3
    Contributors to change in KDIGO risk category *Percentages are based on the total number of patients in each treatment group for each risk category. eGFR, estimated glomerular filtration rate; KDIGO, Kidney Disease: Improving Global Outcomes; Sema, semaglutide; UACR, urine albumin-to-creatinine ratio.